Clinical trials
Observational Hemolysis trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 1 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 1 |
| 2025 | 3 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 15 |
| Recruiting | 7 |
| Unknown status | 7 |
| Withdrawn | 3 |
| Not yet recruiting | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Charles University, Czech Republic | 2 |
| National Heart, Lung, and Blood Institute (NHLBI) | 2 |
| AO GENERIUM | 1 |
| Ain Shams University | 1 |
| Anthea Hospital Bari | 1 |
| Assiut University | 1 |
| Boston Children's Hospital | 1 |
| Cardiologie et Développement | 1 |
| Closed Joint-Stock Company NeoCor | 1 |
| Hanyang University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Hemolysis | 34 |
| Anemia | 5 |
| Anemia, Sickle Cell | 5 |
| Anemia, Hemolytic | 3 |
| Atrial Fibrillation | 2 |
| Hematologic Diseases | 2 |
| Hemoglobinopathies | 2 |
| Hemoglobinuria, Paroxysmal | 2 |
| Hypertension, Pulmonary | 2 |
| Kidney Diseases | 2 |
Trials
Showing 26 to 34 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.